Aptorum Stock Rallies on DiamiR's CLEP Test Approval and Nasdaq Compliance

Aptorum Group Limited (APM) stock is rallying on Thursday due to a merger partner, DiamiR Biosciences Corp., receiving a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health. This milestone expands access to an important tool for risk assessment, clinical trial enrollment, and personalized care strategies for individuals at risk of cognitive decline. The proposed merger between Aptorum and DiamiR is expected to close in Q4 2025.

Aptorum Group Limited (APM) stock experienced a notable rally on Thursday, driven by positive developments from its merger partner, DiamiR Biosciences Corp. DiamiR has received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health. This regulatory milestone expands access to an important tool for risk assessment, clinical trial enrollment, and personalized care strategies for individuals at risk of cognitive decline.

The APOE Genotyping test identifies genetic variants associated with risk for late-onset Alzheimer's disease and other neurological conditions. The test can analyze various biological samples, including blood, buccal swab, saliva, and tissue, and will be available to licensed healthcare providers in New York State and nationwide. The approval represents a significant regulatory milestone for both DiamiR Biosciences and Aptorum Group, aligning with the growing emphasis on biomarker-driven approaches in neurodegenerative disease management.

The timing of this approval is particularly advantageous as the Alzheimer's diagnostic and therapeutic landscape undergoes transformation with recent FDA approvals of disease-modifying treatments. The APOE genotyping test can inform risk stratification, clinical trial enrollment, and personalized treatment strategies, all of which are increasingly important as novel therapeutics for Alzheimer's disease enter the market.

The merger between Aptorum Group and DiamiR Biosciences, announced on July 14, 2025, is expected to close in the fourth quarter of 2025. This merger aims to leverage DiamiR's innovative diagnostic capabilities to expand Aptorum's diagnostic portfolio for neurodegenerative diseases with significant market potential.

References:
[1] https://www.stocktitan.net/news/APM/diami-r-biosciences-and-aptorum-group-announce-new-york-state-uc3ejfccta5c.html